| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Investigative Ophthalmology & Visual Science, Vol 39, 526-531, Copyright © 1998 by Association for Research in Vision and Ophthalmology
ARTICLES AND REPORTS |
JC Morrison, KB Nylander, AK Lauer, WO Cepurna and E Johnson
Kenneth C. Swan Ocular Neurobiology Laboratory, Casey Eye Institute, Oregon Health Sciences University, Portland 97201, USA.
PURPOSE: To determine whether chronic topical glaucoma therapy can control intraocular pressure (IOP) and protect nerve fibers in a rat model of pressure-induced optic nerve damage. METHODS: Sixteen adult Brown Norway rats were-administered unilateral episcleral vein injections of hypertonic saline to produce scarring of the aqueous humor outflow pathways. Twice daily applications of either artificial tears (n = 6), 0.5% betaxolol (n = 5), or 0.5% apraclonidine (n = 5) were delivered to both eyes, and awake pressures were monitored with a TonoPen XL tonometer for 17 days before the rats were killed. RESULTS: For animals administered artificial tears, the mean IOP of the experimental eyes was 39 +/- 2 mm Hg compared with 29 +/- 1 mm Hg for the control eyes. This difference was statistically significant (P < 0.001). Mean IOPs in the experimental eyes of animals administered betaxolol and apraclonidine were 29 +/- 7 and 29 +/- 4 mm Hg, respectively, whereas the mean IOP in the control eyes was 28 +/- 1 mm Hg for both groups. There was no statistically significant difference among these values. The mean IOP for the experimental eyes in the betaxolol and apraclonidine groups was lower than that in animals administered artificial tears (P = 0.003). Quantitative histologic analysis of optic nerve damage in experimental eyes showed that four of the six animals administered artificial tears had damage involving 100% of the neural area. This degree of damage appeared in only 3 of 10 animals administered glaucoma therapy. Optic nerve protection was closely correlated with IOP history because damage was limited to less than 10% of the cross-sectional area in all animals in which the maximal IOP was less than or equal to 39 mm Hg, more than 2 SD below the mean value for eyes administered artificial tears. CONCLUSIONS: Topical glaucoma therapy in this model can prevent IOP elevation and protect optic nerve fibers.
This article has been cited by other articles:
|
|
 |
|
  B. C. Chauhan, T. L. LeVatte, K. L. Garnier, F. Tremblay, I.-H. Pang, A. F. Clark, and M. L. Archibald Semiquantitative Optic Nerve Grading Scheme for Determining Axonal Loss in Experimental Optic Neuropathy Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 634 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Huang, J. B. Fileta, A. Dobberfuhl, T. Filippopolous, Y. Guo, G. Kwon, and C. L. Grosskreutz Calcineurin cleavage is triggered by elevated intraocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma PNAS, August 23, 2005; 102(34): 12242 - 12247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F B Kalapesi, M T Coroneo, and M A Hill Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection Br. J. Ophthalmol., June 1, 2005; 89(6): 758 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-H. Pang, E. C. Johnson, L. Jia, W. O. Cepurna, A. R. Shepard, M. R. Hellberg, A. F. Clark, and J. C. Morrison Evaluation of Inducible Nitric Oxide Synthase in Glaucomatous Optic Neuropathy and Pressure-Induced Optic Nerve Damage Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1313 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. G. Martin, H. A. Quigley, D. J. Zack, H. Levkovitch-Verbin, J. Kielczewski, D. Valenta, L. Baumrind, M. E. Pease, R. L. Klein, and W. W. Hauswirth Gene Therapy with Brain-Derived Neurotrophic Factor As a Protection: Retinal Ganglion Cells in a Rat Glaucoma Model Invest. Ophthalmol. Vis. Sci., October 1, 2003; 44(10): 4357 - 4365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Davies, J. P. Eubanks, and M. R. Powers Increased Retinal Neovascularization in Fas Ligand-Deficient Mice Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 3202 - 3210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Chauhan, J. Pan, M. L. Archibald, T. L. LeVatte, M. E. M. Kelly, and F. Tremblay Effect of Intraocular Pressure on Optic Disc Topography, Electroretinography, and Axonal Loss in a Chronic Pressure-Induced Rat Model of Optic Nerve Damage Invest. Ophthalmol. Vis. Sci., September 1, 2002; 43(9): 2969 - 2976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Baptiste, A. T. E. Hartwick, C. A. B. Jollimore, W. H. Baldridge, B. C. Chauhan, F. Tremblay, and M. E. M. Kelly Comparison of the Neuroprotective Effects of Adrenoceptor Drugs in Retinal Cell Culture and Intact Retina Invest. Ophthalmol. Vis. Sci., August 1, 2002; 43(8): 2666 - 2676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Jia, W. O. Cepurna, E. C. Johnson, and J. C. Morrison Patterns of Intraocular Pressure Elevation after Aqueous Humor Outflow Obstruction in Rats Invest. Ophthalmol. Vis. Sci., May 1, 2000; 41(6): 1380 - 1385. [Abstract] [Full Text]
|
|
|
|
|
|
E. C. Johnson, L. M. H. Deppmeier, S. K. F. Wentzien, I. Hsu, and J. C. Morrison Chronology of Optic Nerve Head and Retinal Responses to Elevated Intraocular Pressure Invest. Ophthalmol. Vis. Sci., February 1, 2000; 41(2): 431 - 442. [Abstract] [Full Text]
|
|
|
|
|
|
K. Sugiyama, Z.-B. Gu, C. Kawase, T. Yamamoto, and Y. Kitazawa Optic Nerve and Peripapillary Choroidal Microvasculature of the Rat Eye Invest. Ophthalmol. Vis. Sci., December 1, 1999; 40(13): 3084 - 3090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Morrison, E. C. Johnson, W. O. Cepurna, and R. H. W. Funk Microvasculature of the Rat Optic Nerve Head Invest. Ophthalmol. Vis. Sci., July 1, 1999; 40(8): 1702 - 1709. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
